COZAAR

This brand name is authorized in Brazil, Canada, Cyprus, Germany, Ecuador, Spain, Finland, France, Hong Kong, Croatia, Ireland, Mexico, Netherlands, Poland, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug COZAAR contains one active pharmaceutical ingredient (API):

1 Losartan UNII 3ST302B24A - LOSARTAN POTASSIUM

Losartan is a synthetic oral angiotensin-II receptor (type AT1) antagonist. Antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade. Read about Losartan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
COZAAR Film-coated tablets	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
COZAAR Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR
COZAAR Powder and solvent for oral suspension	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09CA01	Losartan	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 525500601116311, 525500605111312, 525500606118310
Country: CA	Health Products and Food Branch	Identifier(s): 02182815, 02182874, 02182882
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 00634070
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 24.355-1-01-12, 366780713
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 60913, 62117, 64971
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 006928, 079061
Country: FR	Base de données publique des médicaments	Identifier(s): 66928996, 69197614
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 13583, 13584, 138569, 138571, 142112, 151391, 180547, 198701, 373503, 373620, 374050, 381275, 399367, 94152
Country: HK	Department of Health Drug Office	Identifier(s): 39953, 50281
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-174024498, HR-H-243903537
Country: IE	Health Products Regulatory Authority	Identifier(s): 19020, 19042, 19051, 19065, 19252, 19257, 76510, 76511, 76529
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 284M95
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 41890, 60569
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100016067, 100113936, 100124555
Country: SG	Health Sciences Authority	Identifier(s): 08588P, 11614P
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8683280337053, 8683280337060
Country: US	FDA, National Drug Code	Identifier(s): 0006-0951, 0006-0952, 0006-0960, 55289-238
Country: ZA	Health Products Regulatory Authority	Identifier(s): 29/7.1.3/0268, 36/7.1.3/0490